PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.50%
EBIT growth below 50% of AVXL's 52.11%. Michael Burry would suspect deeper competitive or cost structure issues.
16.24%
Operating income growth under 50% of AVXL's 52.11%. Michael Burry would be concerned about deeper cost or sales issues.
12.65%
Net income growth under 50% of AVXL's 77.47%. Michael Burry would suspect the firm is falling well behind a key competitor.
12.55%
EPS growth under 50% of AVXL's 77.53%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
12.55%
Diluted EPS growth under 50% of AVXL's 77.53%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.30%
Negative OCF growth while AVXL is at 19.70%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-72.30%
Negative FCF growth while AVXL is at 19.70%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-364.91%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-364.91%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-364.91%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-5621.33%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-5621.33%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-5621.33%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-1604.85%
Negative equity/share CAGR over 10 years while AVXL stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-1604.85%
Negative 5Y equity/share growth while AVXL is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-1604.85%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.62%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
6.57%
Debt growth far above AVXL's 1.83%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-21.27%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.